Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
Core issue: The case describes the events which lead to the merger of two large pharmaceutical giant Glaxo welcome and SmithKline beecham which lead to the formation of the entity GlaxoSmithKline. The core concern of the case is that although the newly merged company has invested heavily in R&D there is little evidence of success. Identification of supporting issues: These are some of the other issues that came up in the case which lead to the overall lack of success: * Significant
Premium
healthcare goods. ‚ however there is much dispute over the motives behind the merger and what Glaxo Wellcome sought to gain through the collaboration. This is of particular concern as following the merger‚ many shareholders and city analysts have criticised the firm for not yielding the predicted benefits from the merger‚ particularly with regard to an innovative product pipeline. It has been argued that the purpose of the merger was to serve as a method of consolidating Glaxo Wellcome ’s position in the
Premium Pharmaceutical industry
Jordan Dr. Anne Blanchard English 1101 March 13‚ 2013 How Far is Too Far? In 2012 there were eight major public shootings‚ and since Columbine occurred in April 1999‚ 28 public shootings have occurred. The rate of people who have succumbed to fatal gunshot wounds in public areas has increased to 19.5 times higher than those of similar income countries‚ and there have been at least 61 mass murders since 1982 (Shen‚ Timeline of Mass Shootings). Whenever any type of mass murder occurs‚ the same
Premium Mass murder
history. This project looked at GlaxoSmithKline in Dungarvan‚ Co. Waterford. GSK has been manufacturing in Dungarvan since 1981 and has two manufacturing sites there. The first is the Oral care facility which was set up in 1981 and the second is the over the counter medicine site which was set up in 1987. Many of the company’s flagship brands are produced in Dungarvan including Panadol‚ Polygrip and NiQuitn. According to the GSK Website “Products produced in Dungarvan are exported to more than 70 countries
Premium
Analysis GlaxoSmithKline PLC (NYSE:GSK)‚ formed through the merger of British drug makers Glaxo Wellcome and SmithKline Beecham in December 2000‚ ranks as the world’s second largest pharmaceutical company. GSK group engaged in the creation‚ discovery‚ development‚ manufacture and marketing of pharmaceutical and consumer health-related products. GlaxoSmithKline supply one quarter of the world ’s vaccines and by the end of February 2008 GSK had 24 vaccines in clinical development. It has operations
Premium Pharmaceutical industry
COMPANY OVERVIEW GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. The company is engaged in the discovery‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company primarily operates in 120 countries and its products are sold in more than 150 countries. GSK is headquartered in Brentford‚ the UK and employed 99‚913 people as of December 31‚ 2009. The company recorded revenues of £28‚368
Premium
GlaxoSmithKline (GSK) is one of the largest and most profitable pharmaceutical companies in the world. This conglomerate is the product of multiple mergers of some of the leading companies in the industry. It was created in 2000 and at the time this case was written‚ had a market capitalization of $193.5 billion. The company’s most recent focus is on emerging markets‚ vaccines and consumer healthcare. When Sir Andrew Witty took over as CEO in 2008‚ he implemented a significant restructuring program
Premium Vaccine Pharmacology Pharmaceutical industry
EC229 Economics of Strategy Introduction 1. GlaxoSmithKline (GSK) is a global healthcare company specialized in the research‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company has operations in 120 countries‚ with products being sold in over 150 countries. (Description) 2. As a dominant player in the pharmaceutical industry‚ GSK operates in an oligopolistic market. It is highly cash generative‚ with increased sales growth and shareholder
Premium Costs Economics Oligopoly
Executive Summary Peachtree is a successful and well-established healthcare organization with several institutions including hospitals‚ medical schools and clinics. With their broad market they have reached‚ they need to work on their IT system as the current system consumed so much maintenance time. They have several different incompatible IT systems in their organization amongst the institutions. Therefore Peachtree is looking or a reliable IT system to achieve their objective which is delivering
Premium Health care